[go: up one dir, main page]

BR9801506A - Compostos de quinolina e quinazolina úteis em terapia. - Google Patents

Compostos de quinolina e quinazolina úteis em terapia.

Info

Publication number
BR9801506A
BR9801506A BR9801506-0A BR9801506A BR9801506A BR 9801506 A BR9801506 A BR 9801506A BR 9801506 A BR9801506 A BR 9801506A BR 9801506 A BR9801506 A BR 9801506A
Authority
BR
Brazil
Prior art keywords
chem
formula
optionally substituted
quinoline
therapy
Prior art date
Application number
BR9801506-0A
Other languages
English (en)
Inventor
Alan John Collis
David Nathan Abraham Fox
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9801506A publication Critical patent/BR9801506A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção:<B>"COMPOSTOS DE QUINOLINA E QUINAZOLINA úTEIS EM TERAPIA"<D>. Compostos de fórmula I, em que R^ 1^ representa alcóxi C~ 1~-C~ 4~ facultativamente substituído por um ou mais átomos de flúor, R^ 2^ representa um grupo arilo ou um grupo heteroarilo, facultativamente substituído por alquilo C~ 1~-C~ 4~ ou SO~ 2~NH~ 2~; R^ 3^ representa um anel heterocíclico de 4, 5, 6 ou 7 membros contendo pelo menos um heteroátomo seleccionado de entre N, O e S, sendo o anel facultativamente condensado com um anel de benzeno ou um anel heterocíclico de 5 ou 6 membros contendo pelo menos um heteroátomo seleccionado de entre N, O e S, sendo o sistema de anel como um conjunto facultativamente substituído; X representa CH ou N; e L está ausente, ou representa um grupo cíclico de fórmula Ia, ou representa uma cadeia de fórmula Ib, e seus sais farmaceuticamente aceitáveis, são úteis no tratamento de uma variedade de desordens que incluem a hiperplasia prostática benigna.
BR9801506-0A 1997-05-01 1998-04-29 Compostos de quinolina e quinazolina úteis em terapia. BR9801506A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9708917.1A GB9708917D0 (en) 1997-05-01 1997-05-01 Compounds useful in therapy

Publications (1)

Publication Number Publication Date
BR9801506A true BR9801506A (pt) 2000-02-08

Family

ID=10811691

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9801506-0A BR9801506A (pt) 1997-05-01 1998-04-29 Compostos de quinolina e quinazolina úteis em terapia.

Country Status (10)

Country Link
US (2) US6649620B2 (pt)
EP (1) EP0875506B1 (pt)
JP (1) JP3076786B2 (pt)
AT (1) ATE233242T1 (pt)
BR (1) BR9801506A (pt)
CA (1) CA2236239C (pt)
DE (1) DE69811556T2 (pt)
DK (1) DK0875506T3 (pt)
ES (1) ES2190809T3 (pt)
GB (1) GB9708917D0 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
US6284755B1 (en) 1998-12-08 2001-09-04 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2478500A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US7084156B2 (en) * 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
ES2925655T3 (es) 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
JP4983112B2 (ja) * 2006-06-28 2012-07-25 宇部興産株式会社 ３−（ヒドロキシ又はアルコキシ）−４−アルコキシ−６−ニトロ安息香酸化合物の製法
BRPI0918496A2 (pt) * 2008-09-02 2019-09-24 Novartis Ag composto inibidor bicíclico de quinase, uso do mesmo, composição farmacêutica e método para inibir a atividade da quinase pim em uma célula
KR20250123237A (ko) 2009-01-16 2025-08-14 엑셀리시스, 인코포레이티드 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
HUE055502T2 (hu) * 2012-07-11 2021-11-29 Blueprint Medicines Corp Fibroblaszt növekedési faktor receptor gátlók
CA2928042C (en) 2013-10-25 2022-05-10 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
CN113801069B (zh) * 2020-06-15 2024-03-15 鲁南制药集团股份有限公司 一种盐酸阿夫唑嗪中间体化合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957791A (en) * 1972-09-25 1976-05-18 Sandoz, Inc. Hydroxyalkyl-piperazino-quinoline nitrates
US3956495A (en) * 1973-10-30 1976-05-11 Eli Lilly And Company 2,4-Diaminoquinazolines as antithrombotic agents
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
US4062844A (en) * 1976-09-20 1977-12-13 Pfizer Inc. Process for preparing hypotensive 2-(4-aroylpiperazin-1-yl)-amino-6,7-dimethoxyquinazolines
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
US4189484A (en) * 1977-11-08 1980-02-19 Mitsubishi Yuka Pharmaceutical Co., Ltd. Antihypertensive quinazoline derivatives
US4287341A (en) * 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
US4656174A (en) * 1982-07-24 1987-04-07 Pfizer Inc. Quinoline therapeutic agents
ATE32074T1 (de) * 1983-11-22 1988-02-15 Heumann Ludwig & Co Gmbh Verfahren zur herstellung von 4-amino-6,7dimethoxy-2-(4-(furo-2-yl)-piperazin-1-yl)chinazolin und dessen physiologisch annehmbarer salze.
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
IL88507A (en) 1987-12-03 1993-02-21 Smithkline Beckman Intercredit 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them
US4882337A (en) 1988-08-12 1989-11-21 Pfizer Inc. Tetrahydroisoquinoline antiarrhythmic agents
US5212176A (en) * 1990-06-29 1993-05-18 Abbott Laboratories R(+)-terazosin
CA2148260A1 (en) * 1993-09-10 1995-03-16 Yasutaka Takase Quinazoline cpompounds
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
NZ325248A (en) * 1995-12-23 1999-09-29 Pfizer Res & Dev Quinoline and quinazoline compounds useful in therapy
CA2173408C (en) * 1996-04-03 2001-09-04 K.S. Keshava Murthy Process for the manufacture of intermediates suitable to make doxazosin,terazosin, prazosin, tiodazosin and related antihypertensive medicines
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
US6262269B1 (en) * 1997-02-04 2001-07-17 Trega Biosciences, Inc. 4-Substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
GB9711650D0 (en) * 1997-06-05 1997-07-30 Pfizer Ltd Compounds useful in therapy
WO1999001154A1 (en) * 1997-07-03 1999-01-14 University Of Iowa Research Foundation Method for inhibiting immunostimulatory dna associated responses

Also Published As

Publication number Publication date
DE69811556T2 (de) 2003-08-28
JP3076786B2 (ja) 2000-08-14
CA2236239A1 (en) 1998-11-01
ES2190809T3 (es) 2003-08-16
EP0875506B1 (en) 2003-02-26
EP0875506A1 (en) 1998-11-04
US20030045525A1 (en) 2003-03-06
US20040034032A1 (en) 2004-02-19
GB9708917D0 (en) 1997-06-25
DE69811556D1 (de) 2003-04-03
US6649620B2 (en) 2003-11-18
ATE233242T1 (de) 2003-03-15
JPH10316664A (ja) 1998-12-02
CA2236239C (en) 2003-03-18
DK0875506T3 (da) 2003-03-31

Similar Documents

Publication Publication Date Title
MY119623A (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
ATE255563T1 (de) Therapeutisch nützliche chinoline und quinazoline
CA2236814A1 (en) Quinoline and quinazoline compounds useful in therapy
BR9801506A (pt) Compostos de quinolina e quinazolina úteis em terapia.
DE69838172D1 (de) Oxindolylchinazolinderivate als angiogenesehemmer
DE69331171D1 (de) Chinolin und Chinazolin Derivate zur Behandlung von Arthritis
NO168246C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser.
NO165840C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazo-quinazolinforbindelser.
SE8802412D0 (sv) Thiourea derivatives
AU7810787A (en) 6-{2-(3-phenoxy-2-hydroxy-propylamino)-propyl-amino}-5- methyl-pyrizine-3-one derivatives useful as antihyper- tensive agents
FI914007A0 (fi) 4-substituerade dihydropyrido (4,3-d) pyrimidiner som smaertslindrande och lokala inflammationshaemmande medel vid vaord av hudsjukdomar.
IE873469L (en) Resolution of 1,4-dihydropyridine derivatives
DE68926810D1 (de) Benzoxazepinon-Verfahren
DE3862791D1 (de) N-phenylethylaminoalkyl-benzamide als antiarrhythmische mittel.
ATE112569T1 (de) Verwendung von imidazopyrazolderivaten als analgesische und antiinflammatorische mittel.
ATE79625T1 (de) Substituierte 1,3,4,9-tetrahydropyrano(3,4b&gt;indol-1-essigs|uren.
CO4650138A1 (es) Compuestos de quinolina y de quinazolina utiles en terapia

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1908 DE 31/07/2007.